Editorial Material
Critical Care Medicine
Chuan T. Foo, Anna Paterson, Adam Duckworth, Jurgen Herre
Summary: Malignant pleural effusion is common in mesothelioma, with the presence of hyaluronic acid contributing to its viscosity. Intrapleural hyaluronidase can effectively reduce fluid viscosity and drainage duration, demonstrating feasibility and safety in managing hyaluronic acid-rich viscous malignant pleural effusion.
Review
Oncology
Alex Dipper, Nick Maskell, Anna Bibby
Summary: Malignant pleural mesothelioma (MPM) presents diagnostic challenges, with ancillary diagnostic tests such as immunocytochemical markers, molecular techniques, diagnostic biomarkers, and imaging discussed in cases where histological samples are unavailable or inconclusive. While no single adjunctive test has the sensitivity and specificity to diagnose MPM in isolation, correlation of pleural fluid cytology with radiology and biomarkers can help make an MDT-consensus diagnosis when invasive tests are not feasible.
Review
Medicine, General & Internal
Valeria Musso, Cristina Diotti, Alessandro Palleschi, Davide Tosi, Alberto Aiolfi, Paolo Mendogni
Summary: The article reviewed the diagnosis and therapeutic options for pleural effusion secondary to malignant pleural mesothelioma. A new algorithm was proposed as a practical aid for clinicians dealing with these patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Beatrice Dozin, Grazia Carbotti, Silvio Roncella, Paola Ferro, Paolo Dessanti, Pier Aldo Canessa, Silvano Ferrini, Marina Fabbi
Summary: This study suggests that a high level of IFN-gamma in pleural effusion may be associated with better survival in malignant pleural mesothelioma patients and could potentially serve as a prognostic biomarker. Larger prospective studies are needed to confirm these findings.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Biotechnology & Applied Microbiology
Rumeng Gu, Luxi Jiang, Ting Duan, Chun Chen, Shengchang Wu, Deguang Mu
Summary: Sarcomatoid MPM combined with pulmonary embolism is rare with poor prognosis. Clinicians need to be aware of its occurrence and consider other diseases if targeted treatment is ineffective. Pleural biopsy guided by PET-CT is recommended for timely diagnosis in patients with sarcomatoid MPM.
ONCOTARGETS AND THERAPY
(2021)
Article
Oncology
Wasinee Traipipitsiriwat, Chayanon Songsomboon, Detajin Junhasavasdikul, Viboon Boonsarngsuk, Wipawi Klaisuban
Summary: Post-transplantation malignancy is a common complication-related mortality in transplant recipients. This case report highlights the diagnosis of malignant pleural mesothelioma in a kidney transplant patient after 2 years, emphasizing the need for surveillance and early detection of malignancies in transplant recipients.
Article
Oncology
Nicolai B. Palstrom, Martin Overgaard, Peter Licht, Hans C. Beck
Summary: Proteins found in pleural effusion can serve as biomarkers for the diagnosis of malignant pleural mesothelioma (MPM). The identification of these proteins can significantly improve the accuracy of MPM diagnosis. Therefore, analyzing the protein composition of pleural effusion can lead to new diagnostic methods for MPM.
Article
Engineering, Biomedical
Zhenhuan Song, Weizhan Luo, Haichong Zheng, Yunxiang Zeng, Jinlin Wang, Tianfeng Chen
Summary: A translational selenium nanoparticles coated with immune-modulating macromolecule lentinan are designed to restore dysfunctional immune cells in patient-derived malignant pleural effusion microenvironment, enhancing immune responses and inhibiting tumor growth, thereby providing a potential therapeutic strategy for advanced lung cancer patients with MPE.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Biotechnology & Applied Microbiology
Valeria Panzetta, Ida Musella, Sabato Fusco, Paolo A. Netti
Summary: Malignant pleural mesothelioma is a rare but devastating tumor that is difficult to diagnose and treat effectively. Effusion cytology, although used for diagnosis, is time-consuming and has limited sensitivity. Therefore, alternative research methods are needed to support early diagnosis. Mechanobiology offers new perspectives and diagnostic tools for the mechanical and biophysical characterization of malignant pleural mesothelioma cells.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Medicine, General & Internal
Takeshi Saraya, Kosuke Ohkuma, Masachika Fujiwara, Haruyuki Ishii
Summary: Malignant mesothelioma (MM) is difficult to diagnose and it is crucial to differentiate it from lung cancer (LC) for proper treatment. This study analyzed data from 530 patients with pleural effusion and found that pleural carcinoembryonic antigen and hyaluronic acid could be used to differentiate MM from LC. These findings are important for improving diagnostic accuracy and selecting appropriate treatment methods.
Article
Critical Care Medicine
Rachelle Asciak, Nikolaos I. Kanellakis, Anna Bibby, Andrew Kidd, Stephen Gerry, Rachel Mercer, Nick Maskell, Kevin G. Blyth, Peter Fsadni, Stephen Montefort, Ioannis Psallidas, Najib M. Rahman
Summary: This study investigated the association between pleural fluid exposure and survival in patients with malignant pleural mesothelioma. The findings suggest that successful pleurodesis may be associated with improved survival, but the relationship between MPM exposure duration to pleural fluid and survival remains unclear within the limitations of this retrospective study. Future prospective studies are needed to further evaluate this potentially important mechanism.
Article
Medicine, Research & Experimental
Antonia Marazioti, Anthi C. Krontira, Sabine J. Behrend, Georgia A. Giotopoulou, Giannoula Ntaliarda, Christophe Blanquart, Hasan Bayram, Marianthi Iliopoulou, Malamati Vreka, Lilith Trassl, Mario A. A. Pepe, Caroline M. Hackl, Laura Klotz, Stefanie A. Weiss, Ina Koch, Michael Lindner, Rudolph A. Hatz, Juergen Behr, Darcy E. Wagner, Helen Papadaki, Sophia G. Antimisiaris, Didier Jean, Sophie Deshayes, Marc Gregoire, Ozgecan Kayalar, Deniz Mortazavi, Sukru Dilege, Serhan Tanju, Suat Erus, Omer Yavuz, Pinar Bulutay, Pinar Firat, Ioannis Psallidas, Magda Spella, Ioanna Giopanou, Ioannis Lilis, Anne-Sophie Lamort, Georgios T. Stathopoulos
Summary: A portion of human MPM cases have mutations in KRAS, and mouse models suggest that KRAS mutations can lead to MPM, especially when combined with TP53 deletion. These findings indicate that KRAS alterations may play an important and underestimated role in certain MPM patients.
EMBO MOLECULAR MEDICINE
(2022)
Review
Oncology
Melanie Vogl, Anna Rosenmayr, Tomas Bohanes, Axel Scheed, Milos Brndiar, Elisabeth Stubenberger, Bahil Ghanim
Summary: Malignant pleural mesothelioma (MPM) is an aggressive disease with limited treatment options and poor prognosis, with asbestos exposure and chronic inflammation as main risk factors. The suppression of the specific immune system and activation of the innate immune system are crucial drivers of MPM aggressiveness, leading to unfavorable patient outcomes. Identifying new biomarkers can help personalize patient therapy, avoid ineffective treatments, and ultimately improve outcomes in this rare disease.
Review
Medicine, General & Internal
Sam M. Janes, Doraid Alrifai, Dean A. Fennell
Summary: Mesothelioma, mostly caused by asbestos exposure, has a decreasing incidence but high mortality due to late diagnosis and treatment resistance. Pemetrexed-cisplatin and immune checkpoint inhibitors have shown modest survival extension.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Cardiac & Cardiovascular Systems
Maryum Qureshi, Bibhusal Thapa, Sanjeevan Muruganandan
Summary: Malignant pleural mesothelioma (MPM) is a deadly cancer with limited treatment options. Pleural effusion is the common presentation, requiring recurrent procedures for prevention. However, the optimal treatment for recurrent MPM-related effusion is unclear, and non-expandable lung complicates symptom relief. This review discusses the latest advances in managing pleural effusion and non expandable lung related to MPM.
HEART LUNG AND CIRCULATION
(2023)
Article
Oncology
Christiana Magkrioti, Nikos Oikonomou, Eleanna Kaffe, Marios-Angelos Mouratis, Nikos Xylourgidis, Iliana Barbayianni, Petros Megadoukas, Vaggelis Harokopos, Christos Valavanis, Jerold Chun, Alexandra Kosma, Georgios T. Stathopoulos, Evangelos Bouros, Demosthenes Bouros, Konstantinos Syrigos, Vassilis Aidinis
Article
Oncology
Spyridon Champeris Tsaniras, Maria Villiou, Anastassios D. Giannou, Sofia Nikou, Michalis Petropoulos, Ioannis S. Pateras, Paraskevi Tserou, Foteini Karousi, Maria-Eleni Lalioti, Vassilis G. Gorgoulis, Alexandra L. Patmanidi, Georgios T. Stathopoulos, Vasiliki Bravou, Zoi Lygerou, Stavros Taraviras
JOURNAL OF PATHOLOGY
(2018)
Article
Oncology
Ioannis Psallidas, Nikolaos I. Kanellakis, Stephen Gerry, Marie Laetitia Thezenas, Philip D. Charles, Anastasia Samsonova, Herbert B. Schiller, Roman Fischer, Rachelle Asciak, Robert J. Hallifax, Rachel Mercer, Melissa Dobson, Tao Dong, Ian D. Pavord, Gary S. Collins, Benedikt M. Kessler, Harvey I. Pass, Nick Maskell, Georgios T. Stathopoulos, Najib M. Rahman
Article
Biochemistry & Molecular Biology
Chaido Sirinian, Anastasios D. Papanastasiou, Michail Schizas, Magda Spella, Georgios T. Stathopoulos, Maria Repanti, Ioannis K. Zarkadis, Tari A. King, Haralabos P. Kalofonos
Article
Multidisciplinary Sciences
Antonia Marazioti, Ioannis Lilis, Malamati Vreka, Hara Apostolopoulou, Argyro Kalogeropoulou, Ioanna Giopanou, Georgia A. Giotopoulou, Anthi C. Krontira, Marianthi Iliopoulou, Nikolaos I. Kanellakis, Theodora Agalioti, Anastasios D. Giannou, Celestial Jones-Paris, Yoichiro Iwakura, Dimitrios Kardamakis, Timothy S. Blackwell, Stavros Taraviras, Magda Spella, Georgios T. Stathopoulos
NATURE COMMUNICATIONS
(2018)
Article
Multidisciplinary Sciences
Jamie A. Saxon, Hui Yu, Vasiliy V. Polosukhin, Georgios T. Stathopoulos, Linda A. Gleaves, Allyson G. McLoed, Pierre P. Massion, Fiona E. Yull, Zhongming Zhao, Timothy S. Blackwell
SCIENTIFIC REPORTS
(2018)
Article
Multidisciplinary Sciences
Dimitra Kerdidani, Panagiotis Chouvardas, Ares Rocanin Arjo, Ioanna Giopanou, Giannoula Ntaliarda, Yu Amanda Guo, Mary Tsikitis, Georgios Kazamias, Konstantinos Potaris, Georgios T. Stathopoulos, Spyros Zakynthinos, Ioannis Kalomenidis, Vassili Soumelis, George Kollias, Maria Tsoumakidou
NATURE COMMUNICATIONS
(2019)
Article
Nanoscience & Nanotechnology
A. Marazioti, K. Papadia, A. Giannou, G. T. Stathopoulos, S. G. Antimisiaris
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2019)
Letter
Respiratory System
Jan Christian Kaiser, Georgios T. Stathopoulos
EUROPEAN RESPIRATORY JOURNAL
(2020)
Review
Oncology
Magda Spella, Georgios T. Stathopoulos
Summary: Lung adenocarcinoma (LUAD) is the major subtype of lung cancer and presents challenges due to its ability to resist immune defenses. Current immunotherapies aim to overcome this resistance, but personalized immunotherapies may be necessary for more effective treatment.
Article
Oncology
David Brunn, Kati Turkowski, Stefan Gunther, Andreas Weigert, Thomas Muley, Mark Kriegsmann, Hauke Winter, Reinhard H. Dammann, Georgios T. Stathopoulos, Michael Thomas, Andreas Guenther, Friedrich Grimminger, Soni S. Pullamsetti, Werner Seeger, Rajkumar Savai
Summary: The study revealed that the immune modulator IRF9 in lung cancer has oncogenic properties, promoting tumor proliferation and metastasis. Overexpression of IRF9 is associated with decreased patient survival in lung cancer, and it exerts oncogenic activity through regulating the expression of the oncogene versican. Targeted inhibition of IRF9 could be a new treatment option for lung cancer without interfering with TME JAK-STAT signalling.
Article
Respiratory System
Sabine J. Behrend, Georgia A. Giotopoulou, Magda Spella, Georgios T. Stathopoulos
Summary: The cellular origin of lung adenocarcinoma remains a focus of intense research efforts due to the marked cellular heterogeneity and molecular subtype diversity. Controversy exists regarding the tumor-initiating cells of lung adenocarcinoma, which may arise in distal pulmonary regions, affecting both smokers and nonsmokers, and influenced by environmental factors. Research on this topic includes studies in mouse models and human subjects, with a potential case for club cells as the origin of lung adenocarcinomas in smokers.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Biochemistry & Molecular Biology
Camille Schlesser, Thomas Meul, Georgios Stathopoulos, Silke Meiners
Summary: The anti-diabetic drug metformin induces resistance of cancer cells to the proteasome inhibitor Bortezomib by impairing the activity and assembly of the 26S proteasome complexes.
Article
Biochemistry & Molecular Biology
Kristina A. M. Arendt, Giannoula Ntaliarda, Vasileios Armenis, Danai Kati, Christin Henning, Georgia A. Giotopoulou, Mario A. A. Pepe, Laura Klotz, Anne-Sophie Lamort, Rudolf A. Hatz, Sebastian Kobold, Andrea C. Schamberger, Georgios T. Stathopoulos
Summary: KRAS-mutant tumor cells showed exclusive response to KRAS blockade in vivo by co-opting host myeloid cells through C-C-motif chemokine ligand 2 (CCL2)/interleukin-1 beta (IL-1 beta)-mediated signaling loop. In vitro cellular systems are suboptimal for anti-KRAS drug screens and IL-1 beta blockade might be suitable for therapy for KRAS-mutant cancers.
Article
Multidisciplinary Sciences
Yuanyuan Chen, Reka Toth, Sara Chocarro, Dieter Weichenhan, Joschka Hey, Pavlo Lutsik, Stefan Sawall, Georgios T. Stathopoulos, Christoph Plass, Rocio Sotillo
Summary: This study demonstrates that Club cells utilize regeneration mechanisms to develop lung adenocarcinoma (LUAD). Club cells undergo an epigenetic switch and acquire an AT2-like phenotype during tumor formation. This research highlights the significant role of Club cells in the initiation of LUAD.
NATURE COMMUNICATIONS
(2022)